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Background: Malignant bone lymphoma can be classified as primary (PBL) or secondary (SBL) bone lymphoma.
However, the clinico-pathological characteristics and prognostic factors of PBL versus SBL have not yet been well
defined. Whether lymphoma with multifocal bone involvement should be considered as stage IV PBL or SBL still
remain controversial throughout the literature.
Methods: In this study, we retrospectively reviewed 127 patients with bone lymphoma diagnosed from1998 to
2013 at the Moffitt Cancer Center. Patients were classified as PBL (81 cases) and SBL (46 cases) using the 2013 WHO
Classification of Bone/Soft Tissue Tumors and PBL patients were further subdivided into: 1) PBL with unifocal bone
disease (uPBL, 46 cases), 2) PBL with multifocal bone involvement (mPBL, 35 cases). Patient characteristics, survival,
and prognostic factors were analyzed.
Results: Diffuse large B-cell lymphoma (DLBCL) was the most common histological subtype in all three groups
(37/46 of uPBL, 23/35 of mPBL, 23/46 of SBL). B symptoms, lymph node involvement, and bone marrow involvement
were found to be more common in mPB-DLBCL and SB-DLBCL groups than in the uPB-DLBCL group. Femur was found
to be the most common affected site in uPB-DLBCL patients, while spine was most commonly involved in the other
two groups. Survival analysis indicated that uPBL-DLBCL patients had a significantly better progression-free survival
(PFS) and overall survival (OS) than those in the other two groups (P < 0.05). We also found by univariate analysis
that multifocality, and stage IV were significantly poor prognostic factors for both PFS and OS in PBL patients.
Using multivariate analysis, multifocality remained an independent prognostic factor for both PFS and OS
(P = 0.0117, RR: 3.789, 95% CI: 1.275-11.256).
Conclusion: Overall, our results suggest that mPBL is more similar to SBL in characteristics and survival rather
than uPBL, and thus should be better classified and treated as SBL.
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Malignant bone lymphomas are uncommonly encoun-
tered clinically. According to the initial extent of disease,
malignant bone lymphomas can be divided into two
groups: primary bone lymphoma (PBL) and secondary
bone lymphoma (SBL) [1,2]. PBL is an extremely rare
entity, accounting for approximately 7% of malignant
bone tumors, 5% of extra-nodal lymphomas, and <1% of
all non-Hodgkin lymphomas [1,3]. It has been consid-
ered to have the best prognosis of all primary malignant
bone lesions. However, SBL is more common, seen in
approximately 16% to 20% of patients with lymphoma,
and has a relatively poor prognosis [1]. Given their dif-
ferent clinical outcomes and treatment strategies, sub-
classification of bone lymphomas into either primary or
secondary bone lymphomas is critical. A review of the
literature shows that there is no consensus regarding
how to accurately distinguish PBL from SBL. The most
common debate falls in how to subclassify and treat
bone lymphoma when it primarily presents with multi-
focal bone disease with/without regional lymph node
and/or adjacent soft tissue involvement. The reported 5-
year overall survival (OS) rates vary between different
study groups of PBL patients due to different diagnostic
criteria, ranging from less than 36% to more than 88.3%
[4-8]. In addition, the clinico-pathological characteristics
and prognostic factors of PBL versus SBL have not yet
been well studied.
Recently, the 2013 World Health Organization (WHO)
classification of bone/soft tissue tumors [1] defined PBL
as a neoplasm composed of malignant lymphoid cells,
producing one or more masses within bone, without any
supra-regional lymph-node involvement or other extra-
nodal lesions. According to the criteria, bone lymphoma
with/without regional lymph node and without other
extra-nodal lesions was also classified as PBL clinically, re-
gardless of whether the bone lesion occurred unifocally or
multifocally. We recently identified several potential prog-
nostic factors using the new 2013 WHO classification in a
large study-cohort including 70 PBL cases and showed
that soft tissue extension and IPI score were the most im-
portant unfavorable prognostic indicators for both PFS
and OS in PBL [9]. However, limited information was
available per literatures on the prognostic role of multifo-
cality in PBL, and whether PBL with multifocal bone
involvement should be considered as SBL. Here, we con-
ducted a single-center retrospective study in which we
classified bone lymphoma as PBL and SBL using the new
2013 WHO classification of soft tissue neoplasms, further
subcategorized PBL patients into two groups, those with
unifocal bone disease (uPBL) and those with multifocal
bone involvement (≥2 foci) (mPBL), and compared patient
characteristics, treatments and outcome among uPBL,
mPBL and SBL groups, aiming to further explore theclinical and prognostic significance of multifocal bone




Chart records of 145 patients with biopsy-proven malig-
nant bone lymphoma were retrieved from the surgical
pathology files of Moffitt Cancer Center diagnosed over
a 15-year-period (1998–2013), following the guidelines
of the Moffitt Cancer Center Scientific Research Com-
mittee and with the approval of the Institutional Review
Board at the University of South Florida. After an initial
review of the clinical and pathological data, 18 patient
records were excluded because of the inadequacy of sta-
ging and/or follow-up information. Patient characte-
ristics, survival, and prognostic factors were analyzed.
Medical records were reviewed for age, sex, race, in-
volved sites, lactate dehydrogenase (LDH), pathological
diagnosis, treatments, date of diagnosis, lymph node in-
volvement, bone marrow involvement, stage and date of
disease progression, relapse, death, or last follow-up.
Lymph node involvement was demonstrated by a clinical
and imaging enlargement of node (>1.5 cm measured
per the Positron Emission Tomography, PET scan) with
or without an excision biopsy. Our study thus included
127 patients with bone lymphomas. We classified pa-
tients as PBL and SBL using the updated 2013 WHO
criteria for bone/soft tissue tumors [1] and then fur-
ther subcategorized PBL into two subgroups:1) uPBL
(n = 46),2) mPBL(n = 35). Bone marrow involvement
was assessed by an aspiration and bone marrow biopsy
from iliac crest. If the primary lesion is near iliac or
pelvic region, contra-lateral ilic crest is used for the bi-
opsy site. Bone lymphoma with distant bone marrow
involvement as the only other site of extranodal disease
was also classified as PBL (stage IV) in our study, because
a number of previous studies have demonstrated that it
has a similar prognosis to PBL with localized disease
[2,7,10]. Given the relatively rarity of the other histological
subtype, only patients with diffuse large B-cell lymphoma
(DLBCL), were further reviewed for patient characteristics
and analyzed for prognostic factors in the current study.
Histological diagnosis and immunohistochemistry
findings
All patients were diagnosed lymphoma by bone biopsy.
Morphologic assessments in conjunction with flow cy-
tometry (only if fresh tissue had been harvested) or im-
munohistochemical (IHC) study were conducted. The
IHC markers included CD20, PAX-5, CD10, Bcl-2, Bcl-6,
or MUM-1 for DLBCL or large B-cell lymphoma, un-
classifiable, with features between DLBCL and Burkitt
lymphoma (BLUI) and CD30, CD3, CD4, CD8, CD43,
Table 1 Histopathological subtypes of patients with bone
lymphoma
Classification uPBL mPBL SBL
DLBCL, n (%) 37(80.4) 23(65.7) 23(50.0)
Follicular lymphoma, n (%) 4(8.7) 3(8.6) 9(19.6)
Small lymphocytic lymphoma, n (%) 1(2.2) 1(2.9) 0(0)
Marginal zone lymphoma, n (%) 1(2.2) 1(2.9) 2(4.3)
Not further subclassifieda, n (%) 1(2.2) 2(5.7) 1(2.2)
BLUI , n (%) 0 1(2.9) 0(0)
Classical Hodgkin lymphoma, n (%) 1(2.2) 0(0) 10(21.7)
T cell, n (%) 1(2.2)b 4(11.4)c 1(2.2)d
Total, n (%) 46 35 46
Abbreviations uPBL: primary bone lymphoma with unifocal bone disease;
mPBL: primary bone lymphoma with multifocal bone disease; SBL: secondary
bone lymphoma; DLBCL: diffuse large B-cell lymphoma; Large B-cell lymphoma,
unclassifiable, with features intermediate between DLBCL and Burkitt lymhoma:
BLUI; ALCL: anaplastic large T-cell lymphoma; PTCL, NOS: peripheral T-cell
lymphoma, not otherwise specified.
aLow-grade, small B-cell lymphoma no further information for subclassification.
bALCL(n = 1).
cALCL (n = 2), T-lymphoblastic lymphoma (n = 1), and PTCL, NOS (n = 1).
dALCL (n = 1).
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anaplastic large T-cell lymphoma (ALCL).
Staging
Patients were staged retrospectively according to the Ann
Arbor staging system as described before [9]. In all cases,
staging evaluation included 1) a chest X-ray or a com-
puted tomography (CT) scan of the chest, 2) a CT scan or
ultrasonogram of the abdomen and pelvis, 3) whole body
bone scan or positron emission tomography–computed
tomography (PET-CT) scan or magnetic resonance im-
aging (MRI), and 4) bone marrow biopsy of iliac bone.
Survival analysis
Progression-free survival (PFS) was defined as the inter-
val from the date of diagnosis to the date of disease pro-
gression, relapse, or death from any cause. Patients who
showed no progression were censored at the date of
most recent available radiographic imaging. OS was cal-
culated from the date of diagnosis to the date of death
from any cause using the Social Security Death Index
(SSDI). For unknown deaths, patients were censored at
last follow-up. Survival curves were calculated according
to the Kaplan-Meier method and compared using the
log-rank test. Differences were considered significant if
P values were ≤0.05 (two-tailed). Multivariate analysis
was performed using a Cox model using a forward vari-
able selection procedure. Only the variables with signifi-
cant values (P ≤ 0.05) in univariate analysis were included
in the multivariate analysis. All data analyses were per-
formed by SPSS software for windows, version 20 (SPSS
Inc., Chicago, IL).
Results
Histological diagnosis and patient characteristics
The histological classification of our series is shown in
Table 1. DLBCL was the most common histological sub-
type in all three groups. However, the proportion of
DLBCL patients in the SBL group was significantly lower
than that in the uPBL group (23/46, 50% versus 60/71,
85.7%) (P < 0.05). Classical Hodgkin lymphoma and fol-
licular lymphoma were more commonly shown in SBL
group, while only 1 classical Hodgkin lymphoma case
was identified in the PBL groups. T-cell lymphoma is
relatively rare, with four of the total six T-cell lymphoma
cases in the mPBL group. All classical Hodgkin lymph-
oma cases had nodular sclerosis histology. Among the
127 bone lymphoma patients, only two PBL cases were
HIV positive, including one DLBCL and one large B-cell
lymphoma, unclassifiable, with features intermediate be-
tween DLBCL and Burkitt lymphoma (BLUI).
Given the histological heterogeneity and the relative
rarity of the other histological types, only DLBCL pa-
tients were further explored for demographical andclinical characteristics as well as survival. The charac-
teristics of the 83 DLBCL patients are summarized in
Tables 2 and 3. Compared with primary bone DLBCL
with unifocal bone disease (uPB-DLBCL), B symptoms,
lymph node involvement, and bone marrow involvement
were more commonly shown in the other two groups:
primary bone DLBCL with multifocal bone disease
(mPB-DLBCL) and secondary bone DLBCL (SB-DLBCL).
No significant differences regarding age distribution were
shown among three groups.
Femur was most commonly involved in the uPB-
DLBCL group. However, spine was the most common af-
fected site in the other two groups. Pelvis, humerus, and
tibia were also commonly involved in our series.
Most patients in the uPB-DLBCL group were classified
as stage IE (unifocal localized bone lesions without lymph
node involvement). In the mPB-DLBCL group, all patients
were staged as IVE on the basis of multifocal bone in-
volvement. The majority of SB-DLBCL patients were clas-
sified as stage II-IVE. Only 1 patient with SB-DLBCL, who
had presented with unifocal bone disease and without
lymph node or other extra-nodal sites involvement when
disease relapsed, was classified as stage I.
IHC findings
IHC study was performed in only a subset of patients with
PB-DLBCL. The available data are summarized as follows:
approximately half (26/43) were CD10-positive. Bcl-2,
Bcl-6, and MUM-1 expression were detected in 19 of 23
(82.6%), 24 of 27 (88.9%), and 2 of 16 (12.5%) patients, re-
spectively. In situ hybridization using Epstein-Barr virus-
Table 2 Patient demographics and clinical characteristics
of bone DLBCL
Parameter uPB-DLBCL mPB-DLBCL SB-DLBCL
Total 37 23 23
Age range, years 15-89 17-82 29-82
Median age, years 53.0 60.0 54.0
Mean age, years 52.9 53.4 55.0
<60, n (%) 22(59.5) 11(47.8) 15(65.2)
≥60, n (%) 15(40.5) 12(52.2) 8(34.8)
Sex
Male, n (%) 22(59.5) 14(60.9) 9(39.1)
Female, n (%) 15(40.5) 9(39.1) 14(60.9)
Male :female ratio 1.5:1 1.6:1 0.6:1
Race
White, n (%) 33(89.2) 21(91.3) 17(73.9)
Black, n (%) 2(5.4) 1(4.3) 3(13.0)
Unknown, n (%) 2(5.4) 1(4.3) 3(13.0)
B symptoms, n (%) 7(18.9) 8(34.8) 8(34.8)
LDH
Normal 23(79.3) 5(29.4) 8(57.1)







Number of bone sites, n (%)
Unifocal 37(100.0) 0(0) 7(30.4)
Multifocal 0(0) 23(100.0) 16(69.6)
Sites, n (%)
Appendicular 29(78.4) 10(43.5) 7(30.4)
Axial 8(21.6) 2(8.7) 9(39.1)
Both 0(0) 11(47.8) 7(30.4)
Stage, n (%)
IE 30(81.1) 0(0) 1(4.3)
IIE 4(10.8) 0(0) 2(8.7)
IIIE 0(0) 0(0) 0(0)
IVE 3(8.1) 23(100.0) 20(87.0)
Abbreviations uPB-DLBCL: primary bone diffuse large B-cell lymphoma with
unifocal bone disease; mPB-DLBCL: primary bone diffuse large B-cell lymphoma
with multifocal bone disease; SB-DLBCL: secondary bone diffuse large
B-cell lymphoma.
*Patients with regional lymph node enlargement.
**Patients with both regional and supraregional or systemic lymph
node involvements.








Femur 12(32.4) 12(52.2) 7(30.4)
Humerus 6(16.2) 5(21.7) 3(13.0)
Tibia 5(13.5) 6(26.1) 2 (8.7)
Pelvis, n (%) 5(13.5) 13(56.5) 9 (39.1)
Spine, n (%) 7(18.9) 13(56.5) 11 (47.8)
Abbreviations uPB-DLBCL: primary bone diffuse large B-cell lymphoma with
unifocal bone disease; mPB-DLBCL: primary bone diffuse large B-cell lymphoma
with multifocal bone disease; SB-DLBCL: secondary bone diffuse large
B-cell lymphoma.
Table 4 Treatments of bone DLBCL
Parameter Number (%)
uPB-DLBCL mPB-DLBCL SB-DLBCL*
Treatment n = 37 n = 23 n = 12
CMT 11(29.7) 16(69.6) 7(58.3)
RT 1(2.7) 0 0
CMT and RT 24(54.1) 6(26.1) 5(41.7)
No CMT or RT 1(2.7) 1(4.3) 0
Chemotherapy n = 35 n = 22 n = 12
CHOP or CHOP-like CHOP-like 7(20.0) 0 1(8.3%)
CHOP + rituximab 28(80.0) 22(100.0) 11(91.7%)
Abbreviations uPB-DLBCL: primary bone diffuse large B-cell lymphoma with
unifocal bone disease; mPB-DLBCL: primary bone diffuse large B-cell lymphoma
with multifocal bone disease; SB-DLBCL: secondary bone diffuse large B-cell
lymphoma; CMT: chemotherapy; RT: radiation therapy.
*SB-DLBCL with recurrent bone involvement was not included in the table.
Wu et al. BMC Cancer 2014, 14:900 Page 4 of 9
http://www.biomedcentral.com/1471-2407/14/900encoded RNA probe was performed in five PB-DLBCL
cases, with all five being negative.
Besides CD30, CD3, CD4, CD8, CD43, and granzyme
B, ALK IHC staining was performed in all three primary
bone ALCL cases, with two of the three being positive.Treatments
Treatments of DLBCL patients were summarized (Table 4).
Most patients with uPB-DLBCL with received com-
bined modality therapy (chemotherapy and radiother-
apy), whereas more than half of SB-DLBCL patients
with bone involvement at presentation and mPB-DLBCL
patients were treated with chemotherapy alone. Most bone
DLBCL patients received CHOP or CHOP-like chemo-
therapy with rituximab, and only eight DLBCL patients
received CHOP or CHOP-like chemotherapy alone
without rituximab. R-ESHAP (rituximab plus etoposide,
methylprednisolone, cytarabine, cisplatin) was the main
salvage therapy for SB-DLBCL with recurrent bone
involvement.
Survival analysis of patients with bone lymphoma
Patient follow-up time was calculated using reverse
Kaplan-Meier analysis. For 83 bone DLBCL patients, the
median follow-up times for PFS and OS were 28 months
(range, 1–138 months) and 38 months (range, 1–139
months), respectively. PFS and OS data for uPB-DLBCL,
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Figure 1. The 5-year PFS rates were 75.7% for uPB-
DLBCL, 13.4% for mPB-DLBCL, and 22.0% for SB-
DLBCL (Figure 1A). The 5-year OS rates were 83.4% for
uPB-DLBCL, 36.7% for mPB-DLBCL and 41.9% for SB-
DLBCL (Figure 1B). uPBL patients had a significantly
better PFS and OS than those in the other two groups
(PFS: P = 0.001 for uPB-DLBCL vs. mPB-DLBCL, P < 0.001
for uPB-DLBCL vs. SB-DLBCL; OS: P < 0.001 for uPB-
DLBCL vs. mPB-DLBCL, P < 0.001 for uPB-DLBCL vs. SB-
DLBCL). There were no significant differences in either
PFS or OS between the other two groups (PFS: P = 0.732;
OS: P = 0.572).
Similar results were obtained for our total series of
127 bone lymphoma (Additional file 1: Figure S1).Prognostic factor analyses
We analyzed the influence of the following individual
factors on survival in PB-DLBCL patients: age, sex, B
symptoms, LDH, lymph node involvement, bone marrow
involvement, involved sites, the number of bone sites,
stage, and IHC markers (CD10, Bcl-2, Bcl-6, and MUM-
1). In univariate analysis, LDH, involvement of both ap-
pendicular and axial sites multifocality, and stage IV
were significant poor prognostic factors for both PFS
and OS (Table 5). Age ≥ 60 years was also a significant
poor prognostic factor for OS (Table 5). None of the
IHC markers were significant predictors for PFS or OS.
Using Cox regression for multivariate analysis, multi-
focality were independent unfavorable prognostic fac-
tors for both PFS and OS (Table 6). Age ≥ 60 years was
again an independent unfavorable prognostic factor
for OS.
Moreover, as for SBL, we found that all three patients
with recurrent lymphoma presenting with unifocal bone
disease as the only involved site (re-stage I) (one DLBCL,
one low-grade B cell lymphoma, and one classical HodgkinFigure 1 Overall survival (A) and progression-free survival (B) in threelymphoma) survived without disease progression until final
follow-up (3, 104, and 136 months, respectively).Discussion
PBL was first described by Oberling in 1928 [11] and is
thought to be a separate disease entity from conven-
tional nodal or extranodal base lymphoma with an excel-
lent prognosis. Up to now, its definition still remains
controversial, especially regarding whether multifocal
bone involvement by lymphoma at initial presentation
without any supra-regional lymph node involvement and
other extra-nodal disease should be defined as PBL [10].
Of importance, with obvious improvements in imaging
technology in recent decades, the proportion of patients
diagnosed with multifocal bone lymphoma has increased
[7,12]. Thus, these discrepancies in PBL definition and
the improvements in diagnostic procedures have led to
difficulties in the comparison of clinic-pathological char-
acteristics and clinical outcomes between studies. In
addition, it also raises the question regarding whether
multifocality of bone lymphoma should be considered as
an independent prognostic predictor. Although there
have been several studies on malignant bone lymphoma,
these have thus far been limited by small sample sizes
and/or have included only early-stage PBL cases [4,13,14].
Here, we describe a relatively large cohort of PBL patients
(n = 81) and a compared group of SBL patients (n = 46) di-
agnosed and treated during 1998–2013 at our institution
with modern and contemporary diagnostic and thera-
peutic modalities. A relatively high proportion of our PBL
patients (43.2%, 35 of 81 cases) presented with multifocal
bone disease. This may be due to the routine use of PET,
CT, MRI, and bone scanning for staging. Because only
bone biopsy-proven cases were selected, the number of
SBL patients was relatively small in our series.
Our initial analysis of patient characteristics (age and sex
distribution) was consistent with previous studies [10,15].groups of bone DLBCL.
Table 5 Univariate analysis of prognostic factors for survival in patients with PB-DLBCL
Parameter PFS OS
3-year 5-year P 3-year 5-year P
Overall, % 60.8 45.9 78.8 68.0
Age 0.278 0.004
<60 years, % 64.5 46.9 87.9 80.6
≥60 years, % 50.3 40.2 57.9 44.3
Sex 0.634 0.410
Male, n (%) 63.9 52.1 80.2 71.0
Female, n (%) 53.4 44.8 71.9 61.4
B symptoms 0.673 0.289
No, % 62.5 52.4 80.5 74.3
Yes, % 50.0 31.5 66.1 45.8
LDH 0.011 0.018
Normal, % 73.6 58.2 89.2 68.2
Elevated, % 34.8 21.9 55.2 38.2
Lymph node involvement 0.143 0.231
No, % 66.8 60.0 81.4 75.1
Yes, % 15.6 2.2 64.0 44.3
Bone marrow involvement 0.719 0.319
No, % 59.1 42.0 80.0 72.3
Yes, % 72.9 72.9 54.9 42.0
Sites 0.022 0.022
Appendicular, % 66.7 51.1 78.4 70.6
Axial, % 59.1 59.1 100.0 100.0
Both, % 5.6 0 61.4 61.4
Number of bone sites 0.001 <0.001
Unifocal, % 75.7 75.7 89.2 83.5
Multifocal, % 36.8 13.4 53.1 36.7
Stage 0.005 0.001
IE/IIE, % 73.8 73.8 97.1 97.1
IVE, % 43.0 18.0 58.5 49.8
CD10 0.267 0.077
Negative, % 52.9 29.8 76.8 65.2
Positive, % 64.4 55.2 95.7 95.7
Bold values indicate statistical significance (P<0.05).
Table 6 Multivariate analysis of prognostic factors for patients with PB-DLBCL
Parameter PFS OS
RR 95%CI P RR 95%CI P
Number of bone sites 0.015 0.014
Unifocal Reference group Reference group
Multifocal 3.728 1.292-10.754 20.061 1.851-217.377
Age 0.035
<60 years Reference group
≥60 years 15.791 1.215-205.200
Bold values indicate statistical significance (P<0.05).
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higher frequency of B symptoms, lymph node involvement,
and iliac bone marrow involvement than uPB-DLBCL pa-
tients. In previous studies, femur has been reported to be
the most commonly involved site in PBL [3,16,17]. In our
series, femur was also found to be the most common af-
fected site in uPB-DLBCL patients. However, spine was
most commonly involved in mPB-DLBCL and SB-DLBCL.
From this point of view, our results suggest that mPBL is
more similar to clinical characteristics of patients with SBL
rather than with uPBL.
Consistent with previous studies, DLBCL was the most
common histological subtype in our bone lymphoma
series. However, the uPBL group had a significantly higher
proportion of DLBCL (80.4%, 37 of 46 cases) than the SBL
group (50.0%, 23 of 46 cases). Our results indicate that the
histological distributions are different between the uPBL
group and the SBL group.
Regarding the subclassification of PBL, several studies
with small sample sizes have described the IHC charac-
teristics of PB-DLBCL [18-21]. In these previous reports,
approximately half of the PB-DLBCL cases demonstrated
a germinal center B-cell (GCB) phenotype by IHC with
high Bcl-2 and/or Bcl-6 expression and relatively low
MUM-1 expression. We also observed high percentages
of Bcl-2 and Bcl-6 expression in our series. However, in-
complete IHC data of MUM-1 in our study precluded an
accurate subclassification of our PB-DLBCL cases into
GCB or non-GCB subgroups. Despite so, 26 of 43 patients
were able to be classified with PB-DLBCL in our series ac-
cording to CD10-positivity, which meant that at least
60.5% of these patients were of GCB phenotype. Prior
studies have yielded conflicting results about the predict-
ive value of these IHC markers, particularly of CD10 and
GCB stubtype [5,18-21]. Although insufficient for subclas-
sification of GCB or non-GCB subtype of PB-DLBCL, our
limited data showed no association between various
markers (CD10, Bcl-6, Bcl-2, MUM-1) and survival in PB-
DLBCL.
In the study, we temporally subgrouped the patients
with mPBL as stage IV since whether lymphoma with
multifocal bone involvement should be considered as
stage IV PBL or SBL still remain controversial in the lit-
erature. Because of the unequivocal definition of PBL,
some previous studies restricted diagnoses to those with
early-stage PBL (stage IE and IIE) [14,22]. Only a few
studies have focused on the significance of multifocal bone
diseases in PBL [10,15]. In our study, patients classified
with uPB-DBLCL had an excellent prognosis, whereas
those with mPB-DLBCL carried a poor prognosis, with
survival being similar to SB-DLBCL. The finding suggests
that those with mPBL would benefit from being classified
as SBL rather than conventional PBL. Further prognostic
factor analyses also revealed that multifocality was anindependent prognostic factor of PB-DLBCL, which also
supports that mPBL may be a different clinical entity from
uPBL. Although unifocal bone lymphoma, in general, can
be eradicated with local radiation in 50% of patients, the
treatment of patients with multifocal osseous disease, es-
pecially those presenting with associated soft tissue inva-
sion or generalized adenopathy, is much less satisfactory
[23]. The treatment modality was also somewhat different
among PB-DLBCL and SB-DLBCL groups in our study.
Most patients with uPB-DLBCL were treated with com-
bined modality therapy (chemotherapy and radiotherapy)
for localized lesions, whereas mPB-DLBCL and SB-DLBCL
typically received chemotherapy alone. Given that mPBL
and SBL patients had similar clinical characteristics, prog-
nosis, and treatment modality, our data suggest that it
would be better to classify so-called “mPBL” as SBL in par-
ticular under the setting of DLBCL. As known, DLBCL
constitutes the majority of PBL. Thus, we consider that the
current definition for PBL might need further clarification.
In clinically and radiologically advanced-stage PBL patients
having multiple bone site involvement, especially in those
with regional lymph node and/or adjacent soft tissue in-
volvement, it may be impossible to distinguish mPBL from
SBL. According to our results, it might not be necessary to
distinguish mPBL from SBL clinically.
In a study by Jawad et al. [10], it was suggested that
the use of the name “PBL” should be limited to those
with truly local disease with a single osseous lesion. This
is also the reason we limited mPBL to those with stage
IV in the study. Although stage IV itself was also a signifi-
cant poor prognostic factor for survival in PBL patients by
univariate analysis, it failed to show independent prognos-
tic significance in multivariate analysis, probably due to
the strong correlation between stage IV and multifocal
bone involvement. Ostrowski et al. [15] also reported that
those with malignant lymphoma with multifocal bone dis-
ease had a significantly poorer survival than those with
unifocal bone involvement. However, their study demon-
strated that prognosis of patients with malignant lymph-
oma with multifocal bone disease was considerably better
than those having SBL. Two main reasons may explain
the difference from our study. First, their SBL group in-
cluded a high proportion of patients with malignant
lymphoma with recurrent bone involvement when com-
pared with our data. Second, their patients with regional
lymph node involvement and/or soft tissue extension were
excluded from the group of multifocal bone involvement.
Furthermore, due to the rarity of PBL patients who
present with regional lymph node and/or bone marrow
involvement, there is no consensus regarding the effects
of regional lymph node or bone marrow involvement on
survival in patients with PBL. No significant association
was observed between regional lymph node or bone mar-
row involvement and survival in our PB-DLBCL patients,
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into PBL rather than SBL with a relatively worse progno-
sis. However, our results should be interpreted with cau-
tion given the small sample size.
As for SBL, although recurrent lymphoma is usually
associated with a poor prognosis, we found that patients
with recurrent lymphoma presenting with unifocal bone
disease as the only involved site (re-stage I) had an ex-
cellent prognosis. This result needs careful interpret-
ation, taking into consideration that our study included
only 3 patients with stage I SBL.
It has been mentioned that low grade B-cell lymph-
oma, T-cell lymphoma and Hodgkin lymphoma have
also been included in the study. As the minority in PBL,
we are unable to perform risk stratification for these lymph-
omas. Multicenter studies with larger number of cases are
warranted to explore their prognostic values in PBL. How-
ever, it is of worthy for us to learn several interesting find-
ings in the study. Our series also confirms that primary
bone Hodgkin lymphoma is extremely rare (1 of 81 PBL
patients) in contrast to secondary bone Hodgkin lymphoma
(10 of 46 patients, 21.8%) as reported in literatures, 10-20%
[3,17]. Only five primary T-cell lymphoma cases (including
3 ALCLs) were included in our PBL series. All five cases
showed rapid disease progression within the first year after
diagnosis, with three deceased 4–8 month after diagnosis
(data not shown). Consistent with our results, in the study
by Hsieh et al. [5], all five patients with primary bone T-cell
lymphoma (including 4 ALCLs) with follow-up information
died within 1 year. Limited case number precludes a further
prognostic analysis. Similarity also applies to primary bone
Hodgkin lymphoma. Given the small case number and
histological heterogeneity in low grade B-cell lymphomas,
no further studies have been conducted in our study, either.Conclusions
In summary, our study retrospectively described our sin-
gle institution experience with 127 bone lymphoma pa-
tients, including 81 cases of PBL and 46 cases of SBL using
the new 2013 WHO criteria. Patients with mPB-DLBCL
and SB-DLBCL showed similar characteristics, with both
having a poorer outcome, whereas uPB-DLBCL patients
demonstrated somewhat different characteristics and had
an excellent outcome. Moreover, multifocality was found
to be an independent prognostic factor of PB-DLBCL. Due
to the similar patient characteristics and outcome, it would
be better to classify bone lymphoma presenting with multi-
focal bone disease as SBL rather than conventional PBL,
regardless of whether there is supraregional lymph node or
other extranodal site involvement. Our results indicate that
the current criteria for PBL need further clarification, and
it might be unnecessary to distinguish mPBL from SBL,
clinically. Given the relatively small sample size of patientswith SBL and the incomplete IHC data, our results warrant
further clarification in large multicenter studies.
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